Headquartered in Berkeley Heights, NJ Fiscal year ends December NASDAQ: TNXP tonixpharma.com
Tonix Pharmaceuticals is a fully integrated, commercial-stage biopharmaceutical company focused on central nervous system (CNS) disorders, infectious diseases, immunology conditions, and rare diseases with high unmet medical needs. Its flagship product, TONMYA (cyclobenzaprine HCl sublingual tablets), is a centrally acting, non-opioid analgesic approved for the treatment of fibromyalgia in adults, launched commercially in November 2025. Tonix also markets Zembrace SymTouch (sumatriptan injection) and Tosymra (sumatriptan nasal spray) for acute migraine treatment. The company's development pipeline includes TNX-102 SL in Phase 2 for major depressive disorder and acute stress disorder, TNX-4800 (anti-OspA monoclonal antibody) for Lyme disease prevention, TNX-801 (horsepox live virus vaccine) for smallpox and mpox prevention, TNX-1500 (anti-CD40L monoclonal antibody) for kidney transplant rejection, TNX-1300 (cocaine esterase with Breakthrough Therapy designation) for cocaine intoxication, TNX-2900 (intranasal potentiated oxytocin) for Prader-Willi syndrome, and TNX-4200 (broad-spectrum antiviral) supported by a Department of Defense contract. The company trades on Nasdaq under the ticker TNXP. Updated
A new fibromyalgia drug just reached tens of millions of Medicare members, and patients are already assuming their costs are settled. One document their insurer controls will tell a very different story…
Gerelyn Terzo These nine stocks made big moves, up or down, after the close on Monday, July 20, 2020.
Tonix Pharmaceuticals is a fully integrated, commercial-stage biopharmaceutical company focused on central nervous system (CNS) disorders, infectious diseases, immunology conditions, and rare diseases with high unmet medical needs.
The Wall Street consensus 12-month price target for TNXP is $44.25.
